Colorectal cancer trials in Germany

In Germany 104 Also abroad 1929

104 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 1Taking people
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Where
Berlin, Bochum, Dresden, Duesseldorf, Hamburg, Heilbronn, Munich, Ulm
Age
18 years and over
People
542 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT04929223 · EU 2023-505163-37-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Where
Berlin, Bonn, Hamburg
Age
18 years and over
People
900 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT07228832
Phase 3Taking people
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Where
Amberg, Berlin, Bochum, Dresden, Frankfurt am Main, Hamburg, Leipzig, Mainz, Munich
Age
18 years and over
People
1,020 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07549412 · EU 2025-524648-37-00
Phase 3Taking people
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Where
Berlin, Essen, Frankfurt Am Main, Hamburg
Age
18 years and over
People
477 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06997497 · EU 2024-517232-22-00
Phase 1Taking people
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Where
Erlangen, Essen, München
Age
18 years and over
People
421 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Essen
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 1/2Taking people
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Where
Hamburg, Munich
Age
18 years and over
People
225 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05379595 · EU 2023-506517-22-00
Phase 3Taking people
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Where
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg Im Breisgau, Hamburg, Heidelberg, Mainz, Munich, Ulm
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06662786 · EU 2024-513852-13-00
Phase 3Taking people
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Where
Berlin, Frankfurt am Main, Heidelberg, Mainz, Munich
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06750094 · EU 2024-513853-66-00
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Berlin, Deggendorf, Hamburg
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Where
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Luebeck, Munich, Regensburg
Age
18 years and over
People
700 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07284849 · EU 2025-523735-19-00
Phase 1/2Taking people
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
Where
Bonn, Ulm
Age
18 years and over
People
220 worldwide
Run by
Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00
No phaseTaking people
Rectus Sheath Catheters Following Midline Laparotomy
Where
Schwedt
Age
18 years and over
People
40
Run by
Asklepios Kliniken Hamburg GmbH
See details and how to joinNCT07099924
Phase 3Not yet taking people in Germany
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
Where
Bochum, Dresden, Duesseldorf, Essen, Goettingen, Hamburg, Heilbronn, Leipzig, Munich, Oldenburg in Holstein
Age
18 years and over
People
450 worldwide
Run by
Genmab A/S
See details and how to join2026-525883-17-00 · EU 2026-525883-17-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2/3Taking people
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Where
Berlin, Bochum, Chemnitz, Dresden, Duesseldorf, Erlangen, Frankfurt am Main, Goettingen, Hamburg, Hannover, Leipzig, Mainz, Mannheim, Munich, Ulm
Age
18 years and over
People
990 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07221357 · EU 2025-523224-45-00
Phase 2Taking people
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Where
Berlin, Essen, Frankfurt am Main, Hamburg, Oldenburg, Schweinfurt, Ulm
Age
18 years and over
People
140 worldwide
Run by
Vividion Therapeutics, Inc.
See details and how to joinNCT07811193 · EU 2026-525507-26-00
Phase 2Taking people
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Where
Hamburg, Hanover, Leipzig
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06607458
Phase 1/2Taking people
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Where
Bochum, Düsseldorf, Frankfurt am Main, Lübeck, München
Age
18 years and over
People
346 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06885034
Phase 3Taking people
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Where
Berlin, Bonn, Dresden, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Mainz, Munich, Reutlingen
Age
18 years and over
People
990 worldwide
Run by
AbbVie
See details and how to joinNCT07525206 · EU 2025-521712-19-00
Phase 3Taking people
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
Where
Berlin, Bonn, Dresden, Duesseldorf, Essen, Frankfurt am Main, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Luebeck, Marburg, Munich, Stuttgart, Ulm
Age
18 years and over
People
230 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2025-521587-35-00 · EU 2025-521587-35-00
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Bochum, München, Ulm
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 4Taking people
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
Where
Berlin, Frankfurt am Main, Munich
Age
18 years and over
People
120 worldwide
Run by
Fondazione GONO G.I.
See details and how to join2025-521209-42-00 · EU 2025-521209-42-00